Hyperthermic intraoperative intrapleural chemotherapy and surgical cytoreduction as part of multimodal treatment of malignant pleural mesothelioma – case report M. Szkorupa1, D. Klos1, J. Chudacek1, J. Hanuliak1, M. Stasek1, O. Fischer2, R. Lemstrova3
Authors:
Hyperthermic Intraoperative Intrapleural Chemotherapy; Surgical Cytoreduction As Part Of Multimodal Treatment Of Malignant Pleural Mesothelioma-Case Report; M. Szkorupa 1; D. Klos 1; J. Chudacek 1; J. Hanuliak 1; M. Stasek 1; O. Fischer 2; R. Lemstrová 3
Authors‘ workplace:
I. Chirurgická klinika, Fakultní nemocnice Olomouc
1; Klinika plicních nemocí a tuberkulózy, Fakultní nemocnice Olomouc
2; Onkologická klinika, Fakultní nemocnice Olomouc
3
Published in:
Rozhl. Chir., 2020, roč. 99, č. 10, s. 456-461.
Category:
Case Report
Overview
Malignant pleural mesothelioma is one of the most aggressive malignancies with a very poor prognosis. Multimodal treatment consisting of three modalities – chemotherapy, radiotherapy and cytoreductive surgery is optimal. The use of new therapeutic modalities, such as hyperthermic intraoperative intrapleural chemotherapy or photodynamic therapy can improve the current results of mesothelioma treatment. Combined hyperthermic intraoperative chemotherapy and cytoreductive surgery as part of multimodal therapy of malignant mesothelioma has been used since 2017 at the 1st Department of Surgery of University Hospital Olomouc. The authors report the case of a 47-year-old man with malignant epithelioid mesothelioma of the left pleural cavity. Following neoadjuvant chemotherapy, this patient underwent extrapleural pneumonectomy with intraoperative intracavitary hyperthermic chemotherapy. The postoperative period was complicated by circulatory instability and later by tension fluidothorax with signs of heart failure. Currently, 8 months have elapsed from the surgery and the patient remains without any signs of recurrence.
Sources
- Kolek V, Kašák V, Vašáková M. Pneumologie. Maxdorf 2017.
- Pass HI, Giroux D, Kennedy C, et al. Supplementary prognostic variables for pleural mesothelioma: A report from the IASLC staging committee. Journal of Thoracic Oncology 2014;9(6):856−864. doi: 10.1097/JTO.0000000000000181.
- Davidson B. Prognostic factors in malignant pleural mesothelioma. Human Pathology 2015;46(6):789−804. doi: 10.1016/j.humpath.2015.02.006.
- Tsao AS, Wistuba I, Roth JA. Malignant pleural mesothelioma. Journal of Clinical Oncology 2009;27(12):2081. doi: 10.1200/JCO.2008.19.8523.
- Ricciardi S, Cardillo G, Zirafa CC, et al. Surgery for malignant pleural mesothelioma: An international guidelines review. Journal of Thoracic Disease 2018;10(2):S285. doi: 10.21037/jtd.2017.10.16.
- De Bree E, Van Ruth S, Baas P, et al. Cytoreductive surgery and intraoperative hyperthermic intrathoracic hemotherapy in patients with malignant pleural mesothelioma or pleural metastases of thymoma. Chest 2002;121(2):480−487. doi: 10.1378/chest.121.2.480.
- Bertoglio P, Aprile V, Ambrogi MC, et al. The role of intracavitary therapies in the treatment of malignant pleural mesothelioma. Journal of Thoracic Disease 2018;10(2):S293. doi: 10.21037/jtd.2017.10.165.
- Amin W, Linkov F, Landsittel DP, et al. Factors influencing malignant mesothelioma survival: A retrospective review of The National Mesothelioma Virtual Bank Cohort. F1000research 2018;7. doi: 10.12688/f1000research.15512.3.
- Van Schil PE, Opitz I, Weder W, et al. Multimodal management of malignant pleural mesothelioma: Where are we today? European Respiratory Journal 2014;44:754−764. doi:10,1183 / 09031936,00207213 2014.
- Wald O, Sugarbaker DJ. Malignant pleural mesothelioma: Key determinants in tailoring the right treatment for the right patient. Journal of Thoracic Disease 2017;9(3):485. doi: 10.21037/jtd.2017.03.27.
- Kolek V, Fischer O, Grygárková I, et al. Léčba maligního mezoteliomu pleury v České republice. Studia Pneumologica 2019;79:82.
- De Perrot M, Wu L, Wu M, et al. Radiotherapy for the treatment of malignant pleural mesothelioma. The Lancet Oncology 2017;18(9):E532−E542. doi: 10.1016/S1470-2045(17)30459-X.
- Gomez DR, Rimner A, Simone CB, et al. The use of radiation therapy for the treatment of malignant pleural mesothelioma: Expert opinion from The National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation. Journal of Thoracic Oncology 2019;14(7):1172−1183. doi: 10.1016/S1470-2045(17)30459-X.
- Zhou H, Wu W, Tang X, et al. Effect of hyperthermic intrathoracic chemotherapy (Hithoc) on the malignant pleural effusion: A systematic review and meta-analysis. Medicine 2017;96(1). doi: 10.1097/MD.0000000000005532.
- Lang-Lazdunski L, Bille A, Papa S, et al. Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine, prophylactic radiotherapy, and systemic chemotherapy in patients with malignant pleural mesothelioma: A 10-year experience. The Journal of Thoracic and Cardiovascular Surgery 2015;149(2):558−566. doi: 10.1016/j.jtcvs.2014.10.041.
- Friedberg JS, Simone CB II, Culligan MJ, et al. Extended pleurectomy-decortication–based treatment for advanced stage epithelial mesothelioma yielding a median survival of nearly three years. The Annals of Thoracic Surgery 2017;103(3):912-919. doi: 10.1016/j.athoracsur.2016.08.071.
Labels
Surgery Orthopaedics Trauma surgeryArticle was published in
Perspectives in Surgery
2020 Issue 10
Most read in this issue
- Postoperative chylothorax − review
- Hyperthermic intraoperative intrapleural chemotherapy and surgical cytoreduction as part of multimodal treatment of malignant pleural mesothelioma – case report M. Szkorupa1, D. Klos1, J. Chudacek1, J. Hanuliak1, M. Stasek1, O. Fischer2, R. Lemstrova3
- Role of extracorporeal life support in thoracic surgery
- Malignancy after lung transplantation